Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Mar 11, 2024
- Pharmaceuticals
- R&D
Galderma Announces Nemolizumab Data at American Academy of Dermatology (AAD) Annual Meeting
TOKYO, March 11, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release regarding presentation of the results up to 52 weeks from an interim analysis of the OLYMPIA open-label extension study of nemolizumab in patients with prurigo nodularis, and results from an analysis of two phase III studies (ARCADIA 1 and ARCADIA 2) of nemolizumab at 48 weeks in patients with moderate to severe atopic dermatitis, at American Academy of Dermatology (AAD) Annual Meeting. Nemolizumab is a humanized anti-human IL-31 receptor A monoclonal antibody created by Chugai. Clinical development of nemolizumab outside Japan is being conducted by Galderma.
Please refer to the link below for details of the Galderma’s press release:
Galderma @ AAD 2024: new data demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
